Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

By: via Benzinga
Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.